Cyclopharm Raises $182,500 in Modest Share Purchase Plan Amid Tough Markets

The latest announcement is out from Cyclopharm Limited ( (AU:CYC) ).

Cyclopharm Limited has closed its Share Purchase Plan, raising approximately $182,500 from eligible shareholders through the issue of 192,097 new ordinary shares at $0.95 per share. The offer, extended to 2,200 eligible investors to mirror terms given to institutional and sophisticated participants in its recent capital raising, saw modest uptake amid challenging equity markets and heightened global uncertainty.

Management acknowledged shareholder support during the difficult market environment and confirmed that the new shares are expected to be allotted on 12 March 2026 and quoted on the ASX on 13 March 2026. The SPP shares will rank equally with existing fully paid ordinary shares, slightly bolstering Cyclopharm’s capital position while minimally diluting existing holdings in a period of broader capital markets stress.

The most recent analyst rating on (AU:CYC) stock is a Sell with a A$0.69 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.

More about Cyclopharm Limited

Cyclopharm Limited is an ASX-listed radiopharmaceutical company serving the global medical community. Its core product, Technegas, is used in functional lung ventilation imaging, historically for diagnosing pulmonary embolism and increasingly for conditions such as COPD, asthma, pulmonary hypertension and in certain lung cancer and lung volume reduction procedures.

Average Trading Volume: 89,583

Technical Sentiment Signal: Sell

Current Market Cap: A$88.05M

See more data about CYC stock on TipRanks’ Stock Analysis page.